APEA PMHNP 3P Exam Prep — Comprehensive Study Guide 2026/2027
APEA PMHNP 3P EXAM PREP
Com pr ehensive Study Guide — 2026/2027
Psychiatric-Mental Health Nurse Practitioner Pharmacology, Pathophysiology, Physical Assessment
ANCC PMHNP-BC & AANPCP PMHNP-C Aligned | Questions 41–65 & 146–50 | 30 Targeted Items
Verified Answers with Detailed Rationales | 100% Correct Solutions
Stu dy Gu ide Over view
This APEA PMHNP 3P Exam Prep Comprehensive Study Guide covers the user-specified question
ranges (41–65 and 146–50) from the APEA PMHNP 3P study document. The 30 targeted practice items
address critical domains assessed on PMHNP certification examinations, including
psychopharmacologic management, neurobiological foundations of psychiatric disorders, advanced
mental status and physical assessment techniques, DSM-5-TR diagnostic reasoning, legal and ethical
responsibilities, cultural competence, and scenario-based clinical judgment. All questions are aligned
with ANCC PMHNP-BC Test Content Outline competencies and AANPCP PMHNP-C Examination
Blueprint standards. Correct answers are presented in bold gr een , questions are in bold, and
rationales are in italic font as specified.
Note: Content is high-probability practice material derived from public domain knowledge, APEA PMHNP 3P
course objectives, ANCC/AANPCP examination blueprints, DSM-5-TR criteria, APA Practice Guidelines,
standard PMHNP textbooks (Varcarolis, Keltner, Stahl’s Essential Psychopharmacology), and commonly tested
NP certification concepts. This study guide does not access proprietary APEA, ANCC, or AANPCP examination
content. Always confirm current exam format and requirements directly with APEA (apea.com), ANCC
(nursingworld.org/ancc), or AANPCP (aanpcp.org).
Section A — Qu estions 41–65 (Psychophar m acology,
Pathophysiology, Assessm ent)
41. A 34-year -old patient diagnosed w ith m ajor depr essive disor der (MDD) is
pr escr ibed ser tr aline (Zoloft) 50 m g daily. The patien t r epor ts im pr ovem en t in m ood
after 4 w eeks but now com plains of sign ifi can t sexual dysfun ction , in cludin g
anor gasm ia and decr eased libido. W hich of the follow in g is the m ost appr opr iate
clinical inter vention?
A) Immediately discontinue sertraline and switch to bupropion (Wellbutrin) 150 mg daily
B) Add sildenafil (Viagra) on an as-needed basis for sexual dysfunction
C) Continue sertraline at the current dose and reassure the patient that sexual side effects are
temporary
D) Discuss a tr ial of bupr opion augm en tation or sw itchin g to an antidepr essan t
w ith low er sexual side-eff ect r isk , such as bupr opion or m irtazapin e
Cor r ect Answ er : D
1
, APEA PMHNP 3P Exam Prep — Comprehensive Study Guide 2026/2027
Sexual dysfunction is one of the most common and distressing adverse effects of SSRIs, including
sertraline, occurring in approximately 40% to 70% of patients. The most evidence-based
approach involves either adding bupropion (which has dopaminergic and noradrenergic
activity and minimal sexual side effects) as an augmentation strategy or switching to an
alternative antidepressant with a more favorable sexual side-effect profile. Bupropion
augmentation at 150 mg daily has demonstrated efficacy in multiple randomized controlled
trials for SSRI-induced sexual dysfunction. Immediate discontinuation of sertraline (Option A) is
premature and risks relapse. Adding sildenafil (Option B) may address erectile dysfunction but
does not resolve anorgasmia or decreased libido comprehensively. Reassurance alone (Option C)
is insufficient when evidence-based treatments are available and the patient is significantly
distressed.
42. A 28-year -old w om an w ith bipolar I disor der pr esen ts to the psychiatr ic clin ic for
a m edication r eview . She has been stable on lithium (Lithobid) 900 m g daily for 8
m onths w ith a ther apeutic ser um level of 0.9 m Eq/L. Her m ost r ecen t labor ator y
r esults r eveal a ser um sodium level of 131 m Eq/L an d a thyr oid-stim ulatin g hor m on e
(TSH) level of 6.8 m IU/L (nor m al r an ge: 0.4–4.0 m IU/L). W hich of the follow in g is
the m ost appr opr iate next step in m anagem en t?
A) Discontinue lithium immediately due to the risk of myxedema coma
B) Reduce the lithium dose by 50% and recheck labs in 2 weeks
C) Initiate levothyr oxine r eplacem en t ther apy, coun sel on hydr ation str ategies to
addr ess the hyponatr em ia, and con tin ue lithium at the cur r en t dose
D) Switch to valproate (Depakote) monotherapy
Cor r ect Answ er : C
Lithium is associated with two significant endocrine adverse effects: hypothyroidism (incidence
of 5% to 35%) and nephrogenic diabetes insipidus leading to hypernatremia or, less commonly,
hyponatremia when associated with syndrome of inappropriate antidiuretic hormone secretion
(SIADH). The elevated TSH of 6.8 mIU/L indicates subclinical hypothyroidism, which does not
require immediate lithium discontinuation. The evidence-based approach is to initiate
levothyroxine replacement while maintaining the current therapeutic lithium level, since the
patient is psychiatrically stable. Hyponatremia at 131 mEq/L is mild; counseling on adequate
hydration and monitoring sodium levels is appropriate. Discontinuing lithium (Option A) is
excessive and risks mood destabilization. A 50% dose reduction (Option B) is not indicated
without psychiatric symptoms or toxicity. Switching to valproate (Option D) is premature when
the current adverse effects can be medically managed.
43. A PMHNP is conducting a com pr ehen sive m en tal status exam ination (MSE) on a
45-year-old patient r efer r ed for evaluation of possible schizophr en ia. Dur in g the
MSE, the patient dem onstr ates loosen ess of association s, m ak in g statem ents such as,
"The clouds ar e for m ing m y thoughts today, so the r adio w aves told m e to com e
her e." W hich com ponent of the MSE does this fi n din g m ost dir ectly assess?
A) Thought content
B ) Thought pr ocess
C) Perceptual disturbances
D) Insight and judgment
2
, APEA PMHNP 3P Exam Prep — Comprehensive Study Guide 2026/2027
Cor r ect Answ er : B
Looseness of associations (also known as derailment) is a disorder of thought process, not
thought content. Thought process refers to how a patient connects and organizes ideas logically
and coherently. Looseness of associations, circumstantiality, tangentiality, flight of ideas, and
neologisms are all examples of formal thought disorders that fall under thought process
assessment. Thought content (Option A) would include delusions, obsessions, phobias, ideas of
reference, and suicidal or homicidal ideation. Perceptual disturbances (Option C) encompass
hallucinations (auditory, visual, tactile, olfactory, gustatory). Insight and judgment (Option D)
refer to the patient's awareness of their illness and their ability to make sound decisions
regarding care. The PMHNP must distinguish between process and content abnormalities, as
this differentiation directly informs diagnostic reasoning and treatment planning per DSM-5-TR
criteria.
44. A 22-year -old patient w ith a histor y of atten tion -defi cit/hyper activity disor der
(ADHD) is star ted on lisdexam fetam in e (Vyvan se) 30 m g daily. W hich of the
follow ing instr uctions should the PMHNP pr ovide r egar din g dietar y con sider ation s
w ith this m edication?
A) Avoid consuming tyramine-rich foods such as aged cheese and cured meats
B) Take the medication with a high-fat meal to enhance absorption and duration of effect
C) Ensure adequate vitamin B6 intake, as lisdexamfetamine depletes B6 stores
D) No specifi c dietar y r estr iction s ar e r equir ed; lisdexam fetam in e is a pr odr ug
activated by gastr ointestinal an d r ed blood cell hydr olysis an d is n ot aff ected by
food
Cor r ect Answ er : D
Lisdexamfetamine is a lysine-conjugated prodrug of dextroamphetamine. It is
pharmacologically inactive until it undergoes enzymatic hydrolysis by gastrointestinal and red
blood cell aminopeptidases, converting it to L-lysine and active d-amphetamine. Unlike
immediate-release amphetamine salts, lisdexamfetamine's pharmacokinetics are not
significantly affected by food intake, and no specific dietary restrictions are required. This
contrasts with monoamine oxidase inhibitors (MAOIs), which require strict avoidance of
tyramine-rich foods (Option A) to prevent hypertensive crisis. Taking with a high-fat meal
(Option B) does not meaningfully alter the absorption of lisdexamfetamine as it does with some
extended-release formulations. Vitamin B6 depletion (Option C) is not a recognized interaction
with lisdexamfetamine. The prodrug mechanism provides a slower onset and longer duration of
action, which also reduces abuse potential compared to immediate-release stimulants.
45. A PMHNP is evaluating a 55-year -old patien t w ith tr eatm en t-r esistan t depr ession
(TRD) w ho has failed adequate tr ials of tw o SSRIs an d on e SNRI. The patient ask s
about transcr anial m agnetic stim ulation (TMS) as a tr eatm ent option . W hich of the
follow ing statem ents about TMS is m ost accur ate?
A) TMS requires general anesthesia and is performed in an inpatient hospital setting
B) TMS uses electrical currents delivered directly through the skull to induce therapeutic
seizures
3
APEA PMHNP 3P EXAM PREP
Com pr ehensive Study Guide — 2026/2027
Psychiatric-Mental Health Nurse Practitioner Pharmacology, Pathophysiology, Physical Assessment
ANCC PMHNP-BC & AANPCP PMHNP-C Aligned | Questions 41–65 & 146–50 | 30 Targeted Items
Verified Answers with Detailed Rationales | 100% Correct Solutions
Stu dy Gu ide Over view
This APEA PMHNP 3P Exam Prep Comprehensive Study Guide covers the user-specified question
ranges (41–65 and 146–50) from the APEA PMHNP 3P study document. The 30 targeted practice items
address critical domains assessed on PMHNP certification examinations, including
psychopharmacologic management, neurobiological foundations of psychiatric disorders, advanced
mental status and physical assessment techniques, DSM-5-TR diagnostic reasoning, legal and ethical
responsibilities, cultural competence, and scenario-based clinical judgment. All questions are aligned
with ANCC PMHNP-BC Test Content Outline competencies and AANPCP PMHNP-C Examination
Blueprint standards. Correct answers are presented in bold gr een , questions are in bold, and
rationales are in italic font as specified.
Note: Content is high-probability practice material derived from public domain knowledge, APEA PMHNP 3P
course objectives, ANCC/AANPCP examination blueprints, DSM-5-TR criteria, APA Practice Guidelines,
standard PMHNP textbooks (Varcarolis, Keltner, Stahl’s Essential Psychopharmacology), and commonly tested
NP certification concepts. This study guide does not access proprietary APEA, ANCC, or AANPCP examination
content. Always confirm current exam format and requirements directly with APEA (apea.com), ANCC
(nursingworld.org/ancc), or AANPCP (aanpcp.org).
Section A — Qu estions 41–65 (Psychophar m acology,
Pathophysiology, Assessm ent)
41. A 34-year -old patient diagnosed w ith m ajor depr essive disor der (MDD) is
pr escr ibed ser tr aline (Zoloft) 50 m g daily. The patien t r epor ts im pr ovem en t in m ood
after 4 w eeks but now com plains of sign ifi can t sexual dysfun ction , in cludin g
anor gasm ia and decr eased libido. W hich of the follow in g is the m ost appr opr iate
clinical inter vention?
A) Immediately discontinue sertraline and switch to bupropion (Wellbutrin) 150 mg daily
B) Add sildenafil (Viagra) on an as-needed basis for sexual dysfunction
C) Continue sertraline at the current dose and reassure the patient that sexual side effects are
temporary
D) Discuss a tr ial of bupr opion augm en tation or sw itchin g to an antidepr essan t
w ith low er sexual side-eff ect r isk , such as bupr opion or m irtazapin e
Cor r ect Answ er : D
1
, APEA PMHNP 3P Exam Prep — Comprehensive Study Guide 2026/2027
Sexual dysfunction is one of the most common and distressing adverse effects of SSRIs, including
sertraline, occurring in approximately 40% to 70% of patients. The most evidence-based
approach involves either adding bupropion (which has dopaminergic and noradrenergic
activity and minimal sexual side effects) as an augmentation strategy or switching to an
alternative antidepressant with a more favorable sexual side-effect profile. Bupropion
augmentation at 150 mg daily has demonstrated efficacy in multiple randomized controlled
trials for SSRI-induced sexual dysfunction. Immediate discontinuation of sertraline (Option A) is
premature and risks relapse. Adding sildenafil (Option B) may address erectile dysfunction but
does not resolve anorgasmia or decreased libido comprehensively. Reassurance alone (Option C)
is insufficient when evidence-based treatments are available and the patient is significantly
distressed.
42. A 28-year -old w om an w ith bipolar I disor der pr esen ts to the psychiatr ic clin ic for
a m edication r eview . She has been stable on lithium (Lithobid) 900 m g daily for 8
m onths w ith a ther apeutic ser um level of 0.9 m Eq/L. Her m ost r ecen t labor ator y
r esults r eveal a ser um sodium level of 131 m Eq/L an d a thyr oid-stim ulatin g hor m on e
(TSH) level of 6.8 m IU/L (nor m al r an ge: 0.4–4.0 m IU/L). W hich of the follow in g is
the m ost appr opr iate next step in m anagem en t?
A) Discontinue lithium immediately due to the risk of myxedema coma
B) Reduce the lithium dose by 50% and recheck labs in 2 weeks
C) Initiate levothyr oxine r eplacem en t ther apy, coun sel on hydr ation str ategies to
addr ess the hyponatr em ia, and con tin ue lithium at the cur r en t dose
D) Switch to valproate (Depakote) monotherapy
Cor r ect Answ er : C
Lithium is associated with two significant endocrine adverse effects: hypothyroidism (incidence
of 5% to 35%) and nephrogenic diabetes insipidus leading to hypernatremia or, less commonly,
hyponatremia when associated with syndrome of inappropriate antidiuretic hormone secretion
(SIADH). The elevated TSH of 6.8 mIU/L indicates subclinical hypothyroidism, which does not
require immediate lithium discontinuation. The evidence-based approach is to initiate
levothyroxine replacement while maintaining the current therapeutic lithium level, since the
patient is psychiatrically stable. Hyponatremia at 131 mEq/L is mild; counseling on adequate
hydration and monitoring sodium levels is appropriate. Discontinuing lithium (Option A) is
excessive and risks mood destabilization. A 50% dose reduction (Option B) is not indicated
without psychiatric symptoms or toxicity. Switching to valproate (Option D) is premature when
the current adverse effects can be medically managed.
43. A PMHNP is conducting a com pr ehen sive m en tal status exam ination (MSE) on a
45-year-old patient r efer r ed for evaluation of possible schizophr en ia. Dur in g the
MSE, the patient dem onstr ates loosen ess of association s, m ak in g statem ents such as,
"The clouds ar e for m ing m y thoughts today, so the r adio w aves told m e to com e
her e." W hich com ponent of the MSE does this fi n din g m ost dir ectly assess?
A) Thought content
B ) Thought pr ocess
C) Perceptual disturbances
D) Insight and judgment
2
, APEA PMHNP 3P Exam Prep — Comprehensive Study Guide 2026/2027
Cor r ect Answ er : B
Looseness of associations (also known as derailment) is a disorder of thought process, not
thought content. Thought process refers to how a patient connects and organizes ideas logically
and coherently. Looseness of associations, circumstantiality, tangentiality, flight of ideas, and
neologisms are all examples of formal thought disorders that fall under thought process
assessment. Thought content (Option A) would include delusions, obsessions, phobias, ideas of
reference, and suicidal or homicidal ideation. Perceptual disturbances (Option C) encompass
hallucinations (auditory, visual, tactile, olfactory, gustatory). Insight and judgment (Option D)
refer to the patient's awareness of their illness and their ability to make sound decisions
regarding care. The PMHNP must distinguish between process and content abnormalities, as
this differentiation directly informs diagnostic reasoning and treatment planning per DSM-5-TR
criteria.
44. A 22-year -old patient w ith a histor y of atten tion -defi cit/hyper activity disor der
(ADHD) is star ted on lisdexam fetam in e (Vyvan se) 30 m g daily. W hich of the
follow ing instr uctions should the PMHNP pr ovide r egar din g dietar y con sider ation s
w ith this m edication?
A) Avoid consuming tyramine-rich foods such as aged cheese and cured meats
B) Take the medication with a high-fat meal to enhance absorption and duration of effect
C) Ensure adequate vitamin B6 intake, as lisdexamfetamine depletes B6 stores
D) No specifi c dietar y r estr iction s ar e r equir ed; lisdexam fetam in e is a pr odr ug
activated by gastr ointestinal an d r ed blood cell hydr olysis an d is n ot aff ected by
food
Cor r ect Answ er : D
Lisdexamfetamine is a lysine-conjugated prodrug of dextroamphetamine. It is
pharmacologically inactive until it undergoes enzymatic hydrolysis by gastrointestinal and red
blood cell aminopeptidases, converting it to L-lysine and active d-amphetamine. Unlike
immediate-release amphetamine salts, lisdexamfetamine's pharmacokinetics are not
significantly affected by food intake, and no specific dietary restrictions are required. This
contrasts with monoamine oxidase inhibitors (MAOIs), which require strict avoidance of
tyramine-rich foods (Option A) to prevent hypertensive crisis. Taking with a high-fat meal
(Option B) does not meaningfully alter the absorption of lisdexamfetamine as it does with some
extended-release formulations. Vitamin B6 depletion (Option C) is not a recognized interaction
with lisdexamfetamine. The prodrug mechanism provides a slower onset and longer duration of
action, which also reduces abuse potential compared to immediate-release stimulants.
45. A PMHNP is evaluating a 55-year -old patien t w ith tr eatm en t-r esistan t depr ession
(TRD) w ho has failed adequate tr ials of tw o SSRIs an d on e SNRI. The patient ask s
about transcr anial m agnetic stim ulation (TMS) as a tr eatm ent option . W hich of the
follow ing statem ents about TMS is m ost accur ate?
A) TMS requires general anesthesia and is performed in an inpatient hospital setting
B) TMS uses electrical currents delivered directly through the skull to induce therapeutic
seizures
3
